Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > 60% of the road = 270-days
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1206)
•••
Comment by 99942Apophison Jul 15, 2022 11:11am
234 Views
Post# 34827036

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:60% of the road = 270-days

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:60% of the road = 270-daysScienceFirst wrote
If nasal aerosol deliver more efficiency than shots, it would have been a long time ago that aerosol would have been brought to the forefront as it would have given a hedge to the pharma or biotech that would have  brought it.

Pharmas already have aerosol for some indications but it is based on facts and science.  So if COVID-19 shots would have been the best efficient methods, it would have been brought up.

You definitely have more insight than I do in this matter ScienceFirst however I'm disappointed in your remark simply for the fact that we could also say if TLD-1433 with PDT was more efficient than Radiation & Chemotherapy big Pharma would have developed it already to fight cancer. Perhaps Theralase's nasal via aerosol treatment is what big pharma needs but no one here can really say since its still far too early in their testing! 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities